Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane

Procalcitonin Has a Role to Play in Prediction of Intra-amniotic Subclinical Infection.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02104791

Enrollment

100

Registered

2014-04-04

Start date

2014-05-31

Completion date

Unknown

Last updated

2014-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-amniotic Subclinical Infection.

Keywords

Procalcitonin, intra-amniotic subclinical infection.

Brief summary

It is hypothesized that the procalcitonin has a role to play in prediction of intra-amniotic subclinical infection.

Detailed description

Study population * This study will be conducted at the department of Obstetrics and Gynecology recruiting pregnant women selected from the attendees of antenatal clinic, emergency department and from inpatient wards of Ain Shams University Maternity Hospital from Mars2014. * This study will include 100 pregnant women these cases will be divided into 2 groups: * Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age . * Group 2: Preterm premature rupture of membrane Group: will include 50 pregnant females all at 24-34 weeks of gestational age

Interventions

DRUGprocalcitonin

In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

Patients are with singleton pregnancies. Rupture of membranes will be diagnosed by history, sterile speculum examination to confirm fluid leakage from the cervical canal and ultrasound to confirm oligohydraminos. Subclinical infection will be detected with laboratory indices (WBC count of ≥15, 000 c/mm3, CRP of ≥1 mg/dL) without any clinical symptoms and signs of infection as urinary tract infection in group 1 patients. Women with multiple pregnancies. Clinical signs of infection as (fever,abdominal tendernes). Cervical dilatations of 2 cm or more. Maternal disease like diabetes or fetal complications like intra-uterine fetal death. Inclusion Criteria: \-

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
The correlation between procalcitonin level in PPROM and C-reactive protein level in neonates.	one year	The correlation between procalcitonin level in PPROM and C-reactive protein level in neonates

Secondary

Measure	Time frame	Description
Procalcitonin. - C-reactive protein. - White blood cells count (total and diffrantiated). -C-reactive protein in neonates of groub 2.	one year	Procalcitonin. * C-reactive protein. * White blood cells count (total and diffrantiated). * C-reactive protein in neonates of groub 2.

Other

Measure	Time frame	Description
Procalcitonin. - C-reactive protein. - White blood cells count (total and diffrantiated). -C-reactive protein in neonates of groub 2.	one year	Procalcitonin. * C-reactive protein. * White blood cells count (total and diffrantiated). * C-reactive protein in neonates of groub 2.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026